BPC-157 vs TB-500
Updated: April 25, 2026
| Feature | BPC-157 | TB-500 |
|---|---|---|
| Primary focus | Localized repair signaling | Systemic remodeling discussion |
| Stability class | Standard | Standard |
| Evidence confidence | Medium | Low in this article revision |
Mechanism Comparison
BPC-157 is commonly discussed in targeted tissue recovery contexts, while TB-500 is often framed for broader migration and remodeling pathways. In this revision, BPC-157 has the stronger directly verified citation set; TB-500 is still presented more cautiously.
Stability Comparison
Both compounds require disciplined cold-chain handling and clear concentration labeling. Potency trajectory should be tracked from reconstitution date, not estimated ad hoc.
Clinical Evidence Notes
Evidence quality differs by endpoint and study design. Confidence labels should be interpreted conservatively in workflow planning.
Key Evidence Sources
- BPC-157 wound healing: Sikiric et al. — Stable Gastric Pentadecapeptide BPC 157 and Wound Healing (PMID 34267654, Front Pharmacol 2021)
- BPC-157 tendon repair: Chang et al. — BPC-157 tendon outgrowth and cell survival (PMID 21030672, J Appl Physiol 2011)
- BPC-157 gastric stability: Sikiric et al. — BPC-157 novel therapy in GI tract (PMID 21548867, Curr Pharm Des 2011)
- TB-500 / Thymosin Beta-4 evidence status: This article does not treat TB-500 as equivalently source-validated for wound-healing ranking because the direct citation set was not finalized during review. It remains a lower-confidence comparison target here.
- Stability classifications: ICH Q1A(R2) framework + [Model Estimates — PeptideClock]. Decay rates are not directly derived from peptide-specific shelf-life assays.